StreetInsider.com News Articles

Wave Life Sciences schedules Singapore court hearing for US redomiciliation

Tue, 07 Jul 2026 16:15:12 -0400

Wave Life Sciences Ltd. (NASDAQ: WVE) has scheduled a Singapore High Court hearing for July 14, 2026, to seek approval of a scheme of arrangement that would redomicile the company from Singapore to the United States as a Delaware corporation.

According to a press release, Wave filed its application with the High Court of the Republic of Singapore on July 1, 2026, under case HC/SUM 2058/2026 in HC/OA 434/2026. The hearing is set for 2:30 p.m. Singapore Time at Chamber 2A of the Supreme Court of Singapore.

The court directed that any affidavits in response to the application be submitted by 4:00

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

Tue, 07 Jul 2026 16:15:00 -0400

CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”). The Scheme of Arrangement remains subject to approval by the High Court

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

Tue, 07 Jul 2026 16:15:00 -0400

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

Tue, 07 Jul 2026 16:15:00 -0400

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

Tue, 07 Jul 2026 16:15:00 -0400

Form 8-K Wave Life Sciences Ltd. For: Jun 22

Fri, 26 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260626/26695333.html

Form 8-K Wave Life Sciences Ltd. For: Jun 22

Fri, 26 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260626/26695333.html

Wave Life Sciences starts Phase 2a obesity trial for WVE-007 drug

Wed, 24 Jun 2026 08:30:29 -0400

Wave Life Sciences Ltd. (Nasdaq: WVE) announced it has initiated the Phase 2a portion of its INLIGHT clinical trial evaluating WVE-007, an investigational GalNAc-siRNA therapy targeting obesity and cardiometabolic diseases.

The Phase 2a portion is a placebo-controlled study enrolling individuals with a BMI between 35 and 50 kg/m², with and without type 2 diabetes, across sites in the U.S. and Europe. Participants will be assessed over 12 months across measures including body weight, waist circumference, body composition via MRI and DEXA, liver fat, HbA1c, and lipid levels.

Data from the ongoing Phase 1 single-dose portion of the trial showed that a 240

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

Wed, 24 Jun 2026 08:30:00 -0400

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing

Phase 2a portion in individuals with higher BMI and body fat, with and without type 2 diabetes, includes multiple assessments to inform further development of WVE-007 in obesity as well as MASH, type 2 diabetes, and cardiovascular disease

Wave is on track to initiate additional Phase 2 trials in 2H 2026 evaluating WVE-007 in combination with incretins and as post-incretin maintenance

CAMBRIDGE, Mass., June 24, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

Wed, 24 Jun 2026 08:30:00 -0400

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing

Wave is on track to initiate additional Phase 2 trials in 2H 2026 evaluating WVE-007 in combination with incretins and as post-incretin maintenance

CAMBRIDGE, Mass., June 24, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

Wed, 24 Jun 2026 08:30:00 -0400

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing

Wave is on track to initiate additional Phase 2 trials in 2H 2026 evaluating WVE-007 in combination with incretins and as post-incretin maintenance

CAMBRIDGE, Mass., June 24, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

Wed, 24 Jun 2026 08:30:00 -0400

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing

Wave is on track to initiate additional Phase 2 trials in 2H 2026 evaluating WVE-007 in combination with incretins and as post-incretin maintenance

CAMBRIDGE, Mass., June 24, 2026

H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)

Thu, 11 Jun 2026 06:43:14 -0400

H.C. Wainwright analyst Andrew S. Fein reiterated a Buy rating and $13.00 price target on WAVE Life Sciences (NASDAQ: WVE).

The analyst commented: "We highlight a poster and an oral presentation given by Basecure Therapeutics at the recently concluded ADA 2026 in New Orleans. The bottom line is inhibin knockdown in NHPs shows modest weight loss, however, the inhibin MOA fits squarely with the maintenance profile and quality-weight-loss thesis. Based on the data, we think investors need to focus not on the weight-loss aspect of this class of drug but on the maintenance and quality-of-weight-loss profile, which is what we think

Eco Wave Power featured in second NVIDIA keynote within three months

Tue, 02 Jun 2026 08:31:21 -0400

Eco Wave Power Global AB (NASDAQ: WAVE) appeared in NVIDIA CEO Jensen Huang's GTC Taipei 2026 keynote presentation, marking the second time the wave energy company's technology has been showcased in a flagship NVIDIA keynote within approximately three months.

The company's technology was featured as part of NVIDIA's demonstration of digital twin, simulation, and physical infrastructure applications. The presentation included a digital representation of Eco Wave Power's wave energy technology displaying operational wave and system parameters.

The appearance follows the company's inclusion in NVIDIA's GTC San Jose keynote in March 2026. Eco Wave Power's technology appeared at approximately 18:02 in the GTC

Eco Wave Power featured in second NVIDIA keynote within three months

Tue, 02 Jun 2026 08:31:21 -0400

The appearance follows the company's inclusion in NVIDIA's GTC San Jose keynote in March 2026. Eco Wave Power's technology appeared at approximately 18:02 in the GTC

Eco Wave Power Featured for Second Time in NVIDIA Founder and CEO Jensen Huang's GTC Keynote, as Company Advances Taiwan Wave Energy Project